USA - NASDAQ:TRVI - US89532M1018 - Common Stock
Taking everything into account, TRVI scores 3 out of 10 in our fundamental rating. TRVI was compared to 196 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for TRVI as it has an excellent financial health rating, but there are worries on the profitability. TRVI has a expensive valuation and it also scores bad on growth.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -22.7% | ||
ROE | -23.83% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | 58.73 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 22.42 | ||
Quick Ratio | 22.42 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
8.15
-0.39 (-4.57%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | N/A | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 5 | ||
P/tB | 5 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -22.7% | ||
ROE | -23.83% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 3.29% | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 22.42 | ||
Quick Ratio | 22.42 | ||
Altman-Z | 58.73 |